TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. - Wikidata - wikimedia - TriplyDB

TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial.

TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial.

http://www.wikidata.org/entity/Q42199684

about

Hepatobiliary Tumors: Update on Diagnosis and Management Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis.Addition of n-butyl cyanoacrylate to classic transarterial chemoembolization may improve the radiological response in patients with hepatocellular carcinoma.TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression Aspirin in combination with TACE in treatment of unresectable HCC: a matched-pairs analysis.A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma.New treatment modalities for hepatocellular cancer.Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient.Combination of 5-fluorouracil and 2-morphilino-8-phenyl-4H-chromen-4-one may inhibit liver cancer stem cell activity.NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017 Systemic treatment for hepatocellular carcinoma: Still unmet expectations Pharmacodynamics study of zedoary turmeric oil chitosan microspheres administered via arterial embolization.Role of liver-directed local tumor therapy in the management of hepatocellular carcinoma with extrahepatic metastases: a SEER database analysis.The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy.Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial.Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review.Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis.Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching.Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis The Expanding Role of Systemic Therapy in the Management of Hepatocellular Carcinoma

P2860

Q26775654-568CF630-BD78-47A5-91E5-AEFE81537E03 Q26799469-A3E87800-1E7D-4F27-94B7-7B63377EAC94 Q36210228-85079A49-E872-4B6A-8B27-21BA716705A9 Q36364693-34178770-60F6-4366-96AD-8FFC1ECE04D7 Q36413746-A5E46B29-5AD9-4023-A4F5-234B6600D210 Q37298338-A34B3154-B743-4A63-928B-C7CD2C1ABEB7 Q38375159-5941A31C-F50E-422C-874D-988EF21A4160 Q38419200-007603E6-3C1C-4B46-874B-858C070A3C92 Q38604896-63F6201D-8738-45C3-B2AF-75E5EA564D23 Q38793468-0A2840F1-CAB4-4470-9C28-E9F9D93535EC Q38801422-5AFD3A5E-BC1B-4915-99D8-E4A134DBEA99 Q39112745-552CF874-E05C-45FE-BBA3-1B698523AA91 Q40247978-FCE243B1-0017-4838-9D88-AA7D39AF7542 Q40481465-449C47F4-2C64-4B3B-A1D2-47C60C170D8C Q41172447-0780017F-951F-4315-8ABC-2D21E3870B51 Q42053469-3EDAA9EF-FF0B-4171-908E-B59C23F8CE15 Q42360747-EBFAE4CE-A951-405D-83F3-9A7C0734AE20 Q42371684-ED35EDF8-21AD-45BA-822C-8D6243B2C677 Q47158378-335951F7-DC6F-4DA2-B6CD-52A41128B92C Q52686882-FF583A9A-6D21-473C-BB41-5C64C5D6891B Q58765170-A6A6AA03-D97C-4E14-8DED-785D4995F433 Q58797003-E45E671C-1363-4CC5-B94B-195FD6A74188

P2860

TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial.

http://www.wikidata.org/entity/Q42199684

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

TACE plus sorafenib for the tr ...... nter, phase II SOCRATES trial.

@en

TACE plus sorafenib for the tr ...... nter, phase II SOCRATES trial.

@nl

type

label

TACE plus sorafenib for the tr ...... nter, phase II SOCRATES trial.

@en

TACE plus sorafenib for the tr ...... nter, phase II SOCRATES trial.

@nl

prefLabel

TACE plus sorafenib for the tr ...... nter, phase II SOCRATES trial.

@en

TACE plus sorafenib for the tr ...... nter, phase II SOCRATES trial.

@nl

P1433

Q42199684-530B37E9-D50B-4E42-AC58-C777DE16BAA5

P1476

Q42199684-947BE90D-AD84-4108-91DA-9F14E7654894

P2093

Q42199684-1C5C3691-4D91-48DF-9C07-7A5D34D3831E

Q42199684-2689E339-8B95-48C7-B4BF-075C6B580E7D

Q42199684-44718626-984A-4B52-B5C1-94DD2764D565

Q42199684-5AD80DA4-FF62-4AE9-8AE3-9D24CA02F879

Q42199684-697F758F-7390-4BD3-95DD-71E414D11BC2

Q42199684-A5B9C9BD-43AE-4784-AF4F-8987811D6A77

Q42199684-B2BAF664-2A3C-477F-AEDE-AB6E1853B968

Q42199684-C0197E7A-DBCE-4056-9B7C-1D2026F4931D

Q42199684-D22F16CA-8DC4-4C6F-A9A1-DB975E01870E

Q42199684-E44D5EF4-9BCE-424B-AF6A-D7556A070054

P2860

Q42199684-04FB4578-A57D-40B2-B022-95D8A7242914

Q42199684-0C322ECA-E3FC-43FB-99F6-AE6E3CA85F24

Q42199684-132D71A9-096A-4D50-A984-EB58E4B43E26

Q42199684-1AF0BFEA-13D9-4D50-850F-BC1ADEDC9772

Q42199684-1F525586-0ECB-4755-909E-EBBF0EBDA22A

Q42199684-24527244-6099-4B29-BD9F-49177EB8BB26

Q42199684-37BDCC8C-6EF6-42F1-A8FE-5BF21277651F

Q42199684-3B6BDC17-9C4C-4711-BDD7-FA7963BC22EF

Q42199684-3F942A3F-B19D-43C5-9CCB-35EAD13E4BF1

Q42199684-43DA5251-0C4B-47E9-9FC0-0E0C9CD5CFE8

P2888

Q42199684-4C93166E-B0B6-4631-B1A4-AEDEB59D8B97

P304

Q42199684-CF595AAA-1925-4D38-828E-A89059594B8C

P31

Q42199684-46458649-FAAF-4D28-8222-A143AB4F0A2D

P356

Q42199684-87023D46-135E-4D4B-9FB3-D57FCB5C9D7E

P433

Q42199684-28E14539-768F-463A-8810-B3CE38562B66

P478

Q42199684-57649421-FC7D-49D8-92D8-F18201CCB6A7

P50

Q42199684-632E0D13-2319-46F4-9A78-4AC4AEC77135

P577

Q42199684-CE66FFED-4041-4982-A877-DE46F2CE86F3

P5875

Q42199684-69D92FDC-BDED-450A-90B0-A8397D202D8E

P6179

Q42199684-98CBB9FE-301B-4E19-BF34-CF882D7AE989

P698

Q42199684-9979A715-3C91-4B7E-B30B-84B64BA0E890

P921

Q42199684-8A736C73-60E5-4F0C-8C50-67160176D574

P356

S00280-014-2568-8

P1433

Cancer Chemotherapy and Pharmacology

P1476

TACE plus sorafenib for the tr ...... nter, phase II SOCRATES trial.

@en

P2093

Andreas Erhardt

http://www.w3.org/2001/XMLSchema#string

Christian Ohmann

http://www.w3.org/2001/XMLSchema#string

Christiane Gog

http://www.w3.org/2001/XMLSchema#string

Clemens Walter

http://www.w3.org/2001/XMLSchema#string

Dirk Blondin

http://www.w3.org/2001/XMLSchema#string

Eckart Schott

http://www.w3.org/2001/XMLSchema#string

Frank Kolligs

http://www.w3.org/2001/XMLSchema#string

Frank Lammert

http://www.w3.org/2001/XMLSchema#string

Hennig Wege

http://www.w3.org/2001/XMLSchema#string

Markus Schuchmann

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hepatocellular carcinoma: An update

Global cancer statistics, 2002

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

Sorafenib in advanced hepatocellular carcinoma

Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma

Molecular mechanisms and clinical applications of angiogenesis

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

Management of hepatocellular carcinoma

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.

P2888

s00280-014-2568-8

P304

947-954

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-014-2568-8

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

Dieter Häussinger

P577

2014-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265176620

http://www.w3.org/2001/XMLSchema#string

P6179

1009369776

http://www.w3.org/2001/XMLSchema#string

P698

25173458

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial